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ABSTRACT
Introduction: The efficacy, safety and
tolerability of the preservative-free (PF) fixed
combination (FC) of tafluprost 0.0015% and
timolol 0.5% (once daily) were compared to
those of the individual components (PF
tafluprost 0.0015% once daily and PF timolol
0.5% twice daily) in patients with open-angle
glaucoma or ocular hypertension inadequately
controlled on prior timolol or prostaglandin
monotherapy for 6 months.
Methods: A stratified, double-masked,
randomized, multicenter phase III study was
conducted. A total of 189 prior timolol users
were randomized within the timolol stratum
(TS) to receive either FC (n = 95) or timolol
0.5% (TIM; n = 94). Furthermore, a total of 375
prior prostaglandin analog (PGA) users were
randomized within the prostaglandin stratum
(PS) to receive either FC (n = 188) or tafluprost
0.0015% (TAF; n = 187). To be eligible for
participation in the study, the patients were
required to have an intraocular pressure (IOP)
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of C22 mmHg when on timolol (TIM) or
of C20 mmHg when on PGA in either treated
eye at the screening and end-of-run-in visits. In
addition to these, the study included visits at
baseline, 2 and 6 weeks, 3 and 6 months and at
a post-study visit. IOP was measured at 8 a.m.,
10 a.m., 4 p.m., and 8 p.m.
Results: In the TS, a significant reduction from
baseline IOP was seen with FC and TIM
throughout the study. Average diurnal IOP
change from baseline at month 3 was
-8.55 mmHg (32%) for FC and -7.35 mmHg
(28%) for TIM. The model-based treatment
difference (FC–TIM) was -0.885 mmHg [95%
confidence interval (CI) -1.745 to -0.024;
p = 0.044] demonstrating the superiority of FC
over TIM. In the PS, a significant reduction in
IOP was seen with both FC and TAF throughout
the study. The average diurnal IOP change from
baseline at month 3 was -8.61 mmHg (33%) for
FC and -7.23 mmHg (28%) for TAF. The
model-based treatment difference (FC–TAF)
was -1.516 mmHg (95% CI -2.044 to -0.988;
p\0.001) demonstrating the superiority of FC
over TAF. In the TS, related ocular adverse
events (AEs) were more frequent for patients
treated with FC compared to TIM (16.8% versus
6.4%), whereas related non-ocular AEs were
more frequent with TIM compared to FC
(2.1% versus 0.0%). In the PS, AEs were
similarly distributed between FC and TAF. The
frequency of conjunctival hyperemia of FC was
low (6.4%).
Conclusion: The preservative-free fixed
combination of tafluprost and timolol
provided a substantial and significant IOP
reduction in both strata. The IOP reduction
was superior to both tafluprost 0.0015% and
timolol 0.5% when given as monotherapies.
Overall, the study treatments were safe and well
tolerated.
Funding: Santen Oy, Tampere, Finland.
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INTRODUCTION
The medical treatment of ocular hypertension
and glaucoma is focused on reducing
intraocular pressure (IOP) to reach and
maintain the individual target IOP. However,
for many patients, a single medication is not
sufficient in this respect [1, 2]. If the target IOP
cannot be achieved using a monotherapy, a
combination of drugs with different
mechanisms of action is recommended [3]. In
recent years, the use of fixed combination (FC)
glaucoma medications in patients with
glaucoma or ocular hypertension has
substantially increased. Fixed combinations
contain two medications in a single bottle,
which may be more convenient for the patient
because fewer instillations and bottles are used,
and thus likely improves compliance and
adherence because of the simpler treatment
regimen [4]. Multiple topical therapies may
also be associated with a higher incidence of
side effects [5]. Increased exposure to
preservatives may have untoward effects on
the ocular surface and may lead to a higher
incidence of ocular signs and symptoms, and
poor compliance [4, 6–8]. Benzalkonium
chloride (BAK) is the most widely used
preservative in IOP-lowering ophthalmic
preparations. However, it has been
demonstrated in a variety of experimental
and clinical studies to be pro-apoptotic and
pro-inflammatory, to damage tear film layer,
corneal epithelium and corneal nerves, and has
a negative impact on the number of
conjunctival goblet cells [9–13]. Ocular
surface disease (OSD) and dry eye syndrome
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are frequently detected in patients treated with
preserved glaucoma medications [14, 15]. It
has been shown that OSD is related to the
number of preserved eye drops used, the
prolonged use of preserved medication and
the total benzalkonium chloride (BAK)
exposure [13–16].
The use of preservative-free (PF)
formulations may avoid these negative effects
of BAK [17–19]. Tafluprost ophthalmic solution
0.0015% (TaflotanTM, SaflutanTM, TaprosTM,
Santen, Osaka, Japan) was the first
prostaglandin analog (PGA) that became
available in a PF formulation. The IOP-
lowering efficacy of this PF formulation is
comparable to that of latanoprost [20–22].
PGA/timolol FCs are frequently used in
glaucoma management. Both active
ingredients of these fixed combinations have
a different mode of action [3]. These fixed
combinations provide an IOP reduction of
approximately 30–37% and have to be
instilled only once daily [23, 24]. The
additivity and safety of tafluprost and timolol
administered in a non-fixed combination
(NFC) have been demonstrated in two
randomized, double-masked, parallel-group,
multicenter clinical studies [25, 26]. Thus, PF
prostaglandin/timolol FC for the treatment of
patients with glaucoma and ocular
hypertension may have potential benefits for
patients using fixed combinations of a
prostaglandin analog and timolol.
The present study in patients with open-
angle glaucoma or ocular hypertension was
designed to compare the IOP-lowering efficacy,
safety and tolerability of the PF FC of tafluprost
0.0015% (TAF)/timolol 0.5% (TIM) ophthalmic
solution to those of its individual components,
namely, PF tafluprost 0.0015% and PF timolol
0.5%.
METHODS
Study Design
This was a stratified, double-masked,
randomized, multinational, multicenter phase
III study conducted in 60 centers and 10
countries. The study was registered with
ClinicalTrial.gov #NCT01292460, and was
reviewed and approved by the independent
ethics committees of each participating
country. Prior to enrollment, written informed
consent was obtained from all patients. The
study was conducted in accordance with the
current good clinical practice (GCP)
requirements. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national),
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. A power analysis was
performed to justify the number of patients
enrolled in the study.
Study Population
Male and female patients, aged 18 years and
above, diagnosed with either ocular
hypertension or open-angle glaucoma (primary
open-angle, pseudoexfoliative or pigmentary
glaucoma) in one or both eyes were enrolled
in the study. All patients were required to be
treated either with a PGA [prostaglandin
stratum (PS)] or with timolol 0.5% (TIM)
[timolol stratum (TS)] monotherapy for at least
2 weeks before the screening visit. To be eligible
for study participation, the patients were
required to have IOP in either treated eye
of C22 mmHg at any time of the day during
the screening visit for prior timolol users (TS)
or C20 mmHg for prior prostaglandin analog
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users (PS). Other inclusion criteria were an
increase of at least 2 mmHg in the average
diurnal IOP (measured at 8:00 a.m., 10:00 a.m.,
4:00 p.m and 8:00 p.m.) at the baseline visit as
compared to the average diurnal IOP at the end-
of-run-in period 2 weeks after the screening visit
with either open-label timolol 0.5% (TS) or
tafluprost 0.0015% (PS) treatment and a best
corrected visual acuity no worse than ?0.6
logarithm of the minimal angle of resolution
(logMAR) in both eyes. Exclusion criteria were
pregnancy and planned pregnancy for the study
period; nursing; corneal abnormalities or other
conditions preventing reliable applanation
tonometry; prior refractive eye surgery;
hypersensitivity or contraindication to
tafluprost or timolol; prior filtration surgery or
any other ocular surgery including intraocular
laser procedures within 6 months prior to
screening in the eye(s) to be treated; advanced
visual field defects in either eye or anticipated
progression during the study period; risk for
angle closure (\2 grade anterior chamber angle
width according to Schaffer’s classification); use
of contact lenses at screening or during the
study; and inability to safely discontinue the
use of ocular hypotensive medications during
the wash-out period.
Study Visits and Treatment
The study visits included screening, end-of-run-
in, baseline, 2 and 6 weeks, 3 and 6 months, and
post-study (Fig. 1). At the screening visit, all
eligible patients were assigned according to
their prior treatment regimen [timolol 0.5%
(TIM) or PGA] to receive either PF timolol 0.5%
(TS) twice daily (8:00 a.m. and 8:00 p.m.) or PF
tafluprost 0.0015% (PS) once daily (8:00 a.m.)
for 2 weeks. The run-in period was followed by a
wash-out period of at least 4 weeks. At the
baseline visit, the TS patients were randomized
to receive either PF timolol 0.5% twice daily
(8:00 a.m. and 8:00 p.m.), or PF FC tafluprost
0.0015%/timolol 0.5% at 8:00 a.m. and vehicle
at 8:00 p.m. in the affected eye(s). Accordingly,
the PS patients were randomized to receive PF
tafluprost 0.0015% once daily (8:00 a.m.) or PF
tafluprost 0.0015%/timolol 0.5% FC once daily
(8:00 a.m.) in the affected eye(s) (Fig. 2).
Unilateral dosing of the study medication was
also allowed when the contralateral eye
required no treatment. All study medications
were packed in identical single-dose containers
and pouches for masking.
Efficacy Variables
Diurnal IOP measurements were made by
calibrated Goldmann applanation tonometry
at 8:00 a.m., 10:00 a.m., 4:00 p.m. and 8:00
p.m. during all visits other than screening and
post-study; at these visits, a single IOP
measurement was obtained at any time of the
day. The primary evaluation of IOP was based
on the worse eye and all patients who received
at least one dose of the study medications and
had at least one post-baseline measurement
available [intention to treat (ITT) dataset]. If
both eyes met the IOP criteria at baseline the
eye with the higher IOP at the 8:00 a.m. IOP
measurement was regarded as the worse eye. In
case both eyes had the same IOP at baseline, the
right eye was designated as the study eye. The
primary efficacy variable was the change from
baseline in the average diurnal IOP at month 3.
The primary statistical objective was to
demonstrate that the PF FC tafluprost
0.0015%/timolol 0.5%, administered once
daily in the morning is superior to both
individual components of the FC: PF tafluprost
0.0015% (TAF) administered once daily in the
morning (8:00 a.m.) and PF timolol 0.5% (TIM)
administered twice daily (8:00 a.m. and 8:00
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p.m.). Secondary efficacy variables included the
proportion of responders at month 3 (defined as
change from baseline IOP of 20% or more in
increments of 5%), change from baseline in
mean diurnal IOP at weeks 2 and 6 and month
6, and change from baseline in the time-wise
IOPs at 8:00 a.m., 10:00 a.m., 4:00 p.m., and
8:00 p.m. at weeks 2 and 6 and months 3 and 6.
Safety and Tolerability
The analysis of the safety and tolerability data
was based on all the patients who received at
least one dose of the respective study
medication and had a subsequent safety
measurement. Ocular and non-ocular adverse
events (AEs) were recorded at each visit. Slit
lamp examinations were conducted at each
visit and the findings were graded on a scale
from 0 to 3 (0: normal; 1: mild; 2: moderate; 3:
severe). Central corneal thickness (CCT) was
measured at screening and at month 6 by
ultrasound pachymetry. The severity of
conjunctival hyperemia was assessed from
baseline through month 6 using a set of
reference photographs (redness grading) and a
5-point scale (0: none; 1: mild; 2: moderate; 3:
severe; 4: very severe). Ophthalmoscopic
examinations were conducted via dilated
pupil at screening and at months 3 and 6,
and included the evaluation of vitreous, retina,
and optic nerve head. Visual field testing was
performed at screening and post-study. Drop
discomfort was evaluated at weeks 2 and 6 and
months 3 and 6 on a 4-point scale (0: none, 1:
mild, 2: moderate, 3: severe). Resting blood
pressure and heart rate were measured twice
during the day at 8:00 a.m. and 10:00 a.m.
from baseline visit to month 6.
Statistical Methods
A repeated-measures analysis of the covariance
(RM ANCOVA) model was used to evaluate the
primary efficacy variable within the TS and PS.
A two-sided 95% confidence interval (CI) for the
mean difference estimated from the model was
used for the evaluation of the superiority
hypothesis. Superiority was achieved if the
upper limit of the 95% CI (TS: FC–TIM; PS:
FC–TAF) was less than 0 mmHg or the
corresponding p value was less than 0.05. The
last observation carried forward (LOCF) method
was used for discontinued patients in the ITT
dataset at month 3. A Cochran–Mantel–
Haenszel (CMH) test was used for the
comparison of non-continuous variables
between the two treatment groups. The
planned sample size was 220 enrolled subjects
(110 per arm) in the TS and 380 enrolled
subjects (190 per arm) in the PS. These sample
Screening visit
Visit 1
End-of-run-in visit
Visit 2
At least 14 days
after screening
Baseline visit
Prostaglandin stratum (PS): prior PGA users
End-of-run-in visit Baseline visit
Visit 3
Follow-up visits:
Week 2, Week 6, 
Month 3, Month 6
Day 0 
Visits 4–7
Follow up visits: 
Week 2, Week 6, 
Month 3, Month 6
Post study visit
Post study visit
Visit 8
Timolol stratum (TS): prior timolol users
Wash-out
  period
Fig. 1 An overview of scheduled study visits for both prostaglandin stratum and timolol stratum. PGA prostaglandin
analog, PS prostaglandin stratum, TS timolol stratum
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sizes provided the power of 90% based on
differences of 2.0 mmHg for the TS and
1.5 mm Hg for the PS, a standard deviation
(SD) of 4.0 mmHg for change in IOP, a drop-out
rate of 20% and a two-sided 5% type I error. A
smaller drop-out rate than anticipated was seen
during the study, thus fewer patients could be
randomized in the study without a loss in
statistical power.
RESULTS
In total, 711 subjects were screened for the
study. Of these, 564 patients with open or
ocular hypertension who met the inclusion
criteria were enrolled: 189 patients were
randomized and treated in the TS (n = 95
patients in the FC arm and n = 94 in the TIM
arm) and another 375 patients were randomized
and treated in the PS (n = 188 patients in the FC
arm and 187 patients in the TAF arm) (Fig. 2).
The treatment arms within both strata were
comparable with regard to demographic
characteristics and baseline IOP: the majority
of patients were female and the mean age was
65.7 ± 10.27 years. Primary open-angle
glaucoma was the most frequent diagnosis
(73.9%), followed by ocular hypertension
(22.3%), pseudoexfoliative glaucoma (2.8%)
and pigmentary glaucoma (0.9%). In the TS
and PS, mean baseline IOPs were similar for
both arms at all time points (8:00 a.m., 10:00
a.m., 4:00 p.m. and 8:00 p.m.), and ranged
between 25.9 and 26.9 mmHg in the TS and
25.5 and 26.6 mmHg in the PS, respectively
(Table 1).
A total of 172 patients (91.0%) completed
the 6-month study period in the TS: 86 patients
(FC 90.5%; TIM 91.5%) in both treatment arms.
The most common primary reasons for
termination in the TS were: patient request (3
patients for both FC and TIM), AEs (5 patients
for FC and 1 patient for TIM) and uncontrolled
IOP (1 patient for FC and 2 patients for TIM). In
the PS, a total of 348 patients (92.8%)
completed the 6-month study period: 175
Prior medical therapy
Timolol or PGA Monotherapy
Screened: n = 711r
Prior timolol users
Timolol stratum (TS)
Screened: n = 223
Prior PGA users
PGA stratum (PS)
Screened: n = 488
Patients randomized
n = 189
Patients randomized
n = 375
FC treatment
n = 95
TIM treatment
n = 94
FC treatment
n = 188
TAF treatment
n = 187
PF fixed combination
(once daily) at 8:00 a.m.
and vehicle at 8:00 p.m.
PF timolol 0.5%
(twice daily) at 8:00 a.m.
and 8:00 p.m.
PF fixed combination
(once daily) at 8:00 a.m.
and vehicle at 8:00 p.m.
PF tafluprost 0.0015%
(once daily) at 8:00 a.m.
and vehicle at 8:00 p.m.
Fig. 2 Stratiﬁcation, number of patients, and medical
treatment. FC preservative-free ﬁxed combination
taﬂuprost 0.0015%/timolol 0.5%. PGA prostaglandin
analog, PS prostaglandin stratum, TAF monotherapy
preservative-free taﬂuprost 0.0015%, TIM monotherapy
preservative-free timolol 0.5%, TS timolol stratum
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patients (93.1%) in the FC arm and 173 patients
(92.5%) in the TAF arm. The most common
primary reasons for termination in the PS were:
uncontrolled IOP (5 patients for FC and 8
patients for TAF), AEs (6 patients for FC and 2
patients for TAF) and patient request (2 patients
for FC and 3 patients for TAF).
Only 3 patients had no post-baseline efficacy
data; thus, the ITT datasets included 188 and
373 patients in the TS and PS, respectively: in
the TS, 95 patients treated with the FC and 93
treated with TIM, in the PS 188 patients treated
with FC and 185 patients treated with TAF.
Efficacy in Prior Timolol Users (TS)
A clinically and statistically significant
reduction of IOP from baseline was seen with
Table 1 Demographic and baseline characteristics by treatment group
Timolol stratum (TS) Prostaglandin stratum (PS)
FC (n5 95) TIM (n5 94) FC (n5 188) TAF (n5 187)
Gender, n (%)
Male 44 (46.3) 36 (38.3) 70 (37.2) 61 (32.6)
Female 51 (53.7) 58 (61.7) 118 (62.8) 126 (67.4)
Age (years)
Mean 64.9 67.4 65.4 65.4
SD 10.3 9.2 10.7 10.3
Range 23–84 40–87 27–85 25–87
Central corneal thickness (lm) Right Left Right Left Right Left Right Left
Mean 555 556 554 554 542 541 544 544
SD 36.1 37.4 39.6 43.0 33.6 33.6 34.7 35.7
Range 460–659 475–665 337–640 282–631 442–646 437–635 445–648 448–637
Ocular diagnosis, worse eye n (%)
Ocular hypertension 25 (26.3) 23 (24.5) 39 (20.7) 39 (20.9)
Primary open-angle glaucoma 69 (72.6) 69 (73.4) 140 (74.5) 139 (74.3)
Pseudoexfoliative glaucoma 0 (0.0) 2 (2.1) 7 (3.7) 7 (3.7)
Pigmentary glaucoma 1 (1.1) 0 (0.0) 2 (1.1) 2 (1.1)
Baseline intraocular pressure, mmHg (mean ± SD) ITT dataset
8:00 a.m. 26.94 (2.84) 26.55 (2.32) 26.35 (3.16) 26.59 (3.21)
10:00 a.m. 26.50 (2.33) 26.32 (2.28) 25.93 (3.22) 26.10 (3.01)
4:00 p.m. 26.32 (2.08) 25.97 (2.36) 25.63 (3.17) 25.59 (3.13)
8:00 p.m. 26.19 (2.30) 25.87 (2.64) 25.54 (3.17) 25.61 (2.74)
FC preservative-free ﬁxed combination taﬂuprost 0.0015%/timolol 0.5%, ITT intention to treat, SD standard deviation,
TAF monotherapy preservative-free taﬂuprost 0.0015%, TIM monotherapy preservative-free timolol 0.5%
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both treatment regimens throughout the study,
and low IOP levels were maintained in both
treatment arms up to the 6-month visit. Time-
wise differences at all visits were clearly in favor
of the FC: FC lowered IOP between 7.1 and
9.0 mmHg (within group p\0.001 at all time
points, ITT dataset). In comparison, TIM 0.5%
twice daily lowered IOP between 6.5 and
8.1 mmHg (within group p\0.001 at all time
points, ITT dataset) (Fig. 3). At month 3, the
time-wise differences (FC–TIM) ranged on
average from -1.50 to -0.85 mmHg (Fig. 4),
and the estimated average treatment difference
(FC–TIM) from the primary RM ANCOVA model
for the ITT LOCF dataset was -0.885 mmHg
with a 95% CI from -1.745 to -0.024 mmHg
(p = 0.044), thus superiority of FC over TIM was
achieved (Table 2). The sensitivity analysis
without using the baseline IOP as a covariate
(RM ANOVA) confirmed these results: the
treatment difference at month 3 was
-1.105 mmHg with a 95% CI from -1.995 to
-0.215 mmHg (p = 0.015). IOP levels for all
individual patients in the TS at baseline and at
month 3 and the corresponding box-whisker
plots of mean diurnal IOPs (mmHg) at month 3
versus baseline are shown in Fig. 5. It should be
noted that one outlier had a substantial effect
on the result (Fig. 5a).
The results for all secondary efficacy variables
were well in line with the primary efficacy
variable: the proportion of responders
(reduction of mean IOP of 20, 25, 30, and 35%)
was in favor of the FC in each response category.
A decrease of 35% or more was seen in 33.7% in
the FC treatment arm and 23.7% in the TIM
treatment arm (p = 0.081; CMH-test; ITT LOCF
dataset). It should be noted that TS was not
properly powered for responder analyses.
Furthermore, all estimated time-wise treatment
differences (FC–TIM) were clearly in favor of the
FC and on average around 1 mmHg; the
favorable average difference was sustained up to
month 6 (p = 0.017; RM ANCOVA; ITT dataset).
Efficacy in Prior PGA users (PS)
A clinically and statistically significant
reduction of IOP from baseline was seen with
both treatment regimens throughout the study,
and low IOP levels were maintained in both
treatment arms up to 6 months. Time-wise
differences at all visits were clearly in favor of
the FC: FC lowered IOP between 8.2 and
Table 2 Overall treatment differences in IOP at month 3 (ITT LOCF dataset)—TS and PS. For the TS, the effect of the
outlier is shown separately
RM ANCOVA ITT
dataset (month 3)
PF FC versus monotherapy PF
TIM (primary with outlier)
PF FC versus monotherapy PF
TIM (without outlier)
PF FC versus
monotherapy PF
TAF
Difference (mmHg) -0.885 -1.136 -1.516
Upper 95% CI -0.024 -0.379 -0.988
Lower 95% CI -1.745 -1.897 -2.044
p value 0.044 0.004 \0.001
CI conﬁdence interval, FC preservative-free ﬁxed combination taﬂuprost 0.0015%/timolol 0.5%, IOP intraocular pressure,
ITT intention to treat, LOCF last observation carried forward, PF preservative free, PS prostaglandin stratum, RM
ANCOVA repeat measures analysis of the covariance, TAF monotherapy preservative-free taﬂuprost 0.0015%, TIM
monotherapy preservative-free timolol 0.5%, TS timolol stratum
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9.0 mmHg (within group p\0.001 at all time
points, ITT dataset). In comparison, TAF
lowered IOP between 6.8 and 7.4 mmHg
(within group p\0.001 at all time points, ITT
dataset) (Fig. 6). At month 3, the time-wise
differences (FC–TAF) ranged on average from
-1.76 to -1.03 mmHg (Fig. 4) and the
estimated average treatment difference (FC–
TAF) from the primary RM ANCOVA model
for the ITT LOCF dataset was -1.516 mmHg
with a 95% CI from -2.044 to -0.988 mmHg
(p\0.001), thus the superiority of FC over TAF
was achieved (Table 2). The sensitivity analysis
without the baseline covariate (RM ANOVA)
confirmed these results: the treatment
difference at month 3 was -1.402 mmHg with
a 95% CI from -1.996 to -0.807 mmHg
(p\0.001). IOP levels for all individual
patients in the PS at baseline and at month 3
and the corresponding box-whisker plots of
mean diurnal IOPs (mmHg) at month 3 versus
baseline are shown in Fig. 7.
The results for all secondary efficacy
variables were well in line with the primary
efficacy variable. The proportion of responders
(reduction of mean IOP of 20, 25, 30, and 35%)
was in favor of the FC: in each response
category, there was a clear and statistically
significant advantage in favor of the FC. IOP
reductions of C30% from baseline were
achieved in 61.8% and 37.9% of patients in
the FC and TAF treatment arm, respectively
(p\0.001; CMH-test; ITT LOCF dataset), and
IOP reductions of C35% from baseline was
achieved in 38.2% and 23.6% of patients in
the FC and TAF treatment arm, respectively
(p = 0.002; CMH-test; ITT LOCF dataset.
Furthermore, all estimated time-wise
treatment differences (FC–TAF) were clearly in
favor of the FC, on average around 1.5 mmHg,
and the favorable average difference was
sustained up to 6 months (p\0.001; RM
ANCOVA; ITT dataset).
Ocular and Non-ocular Adverse Events
In the TS, 94 related and non-related AEs (54
ocular, 40 non-ocular) were reported by 43
Fig. 3 Changes of mean (SD) intraocular pressure (IOP)
from baseline at weeks 2 and 6, and months 3 and 6 at 8
a.m., 10 a.m., 4 p.m. and 8 p.m. in the TS. Worse eye
analysis in the ITT dataset. FC preservative-free ﬁxed
combination taﬂuprost 0.0015%/timolol 0.5%, IOP
intraocular pressure, ITT intention to treat, SD standard
deviation, TIM monotherapy preservative-free timolol
0.5%, TS timolol stratum
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patients (45.3%) in the FC treatment arm and
89 AEs (15 ocular, 74 non-ocular) were reported
by 35 patients (37.2%) in the TIM treatment
arm. Overall, there were fewer ocular AEs, but
more non-ocular AEs in the TIM treatment arm
compared to FC. In total, 7 patients (5 in the FC
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Fig. 5 a Scatterplot of mean change in diurnal IOPs
(mmHg) from baseline to month 3 in the TS and
b corresponding box-whisker plot of mean diurnal IOPs
(mmHg) at month 3 versus baseline for FC and TIM. FC
preservative-free ﬁxed combination taﬂuprost 0.0015%/
timolol 0.5%, IOP intraocular pressure, TIM monotherapy
preservative-free timolol 0.5%, TS timolol stratum
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Fig. 4 Changes of mean (SD) intraocular pressure (IOP)
from baseline at month 3 for both strata by treatment
group at 8 a.m., 10 a.m., 4 p.m., and 8 p.m.. Worse eye
analysis in the ITT dataset. FC preservative-free ﬁxed
combination taﬂuprost 0.0015%/timolol 0.5%, IOP
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prostaglandin analog, PS prostaglandin stratum, SD standard
deviation, TAF monotherapy preservative-free taﬂuprost
0.0015%, TIM monotherapy preservative-free timolol
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and 2 in the TIM treatment arm) discontinued
the study due to AEs in the TS. Treatment-
related AEs leading to study termination of 4
patients in the TS were ocular in all cases in the
FC treatment arm. These included: erythema of
the eyelid, eyelid pain, ocular discomfort,
conjunctival/ocular hyperemia, photophobia,
blepharitis, madarosis, meibomianitis and eye
pruritus. Both terminations in the TIM
treatment arm were due to AEs which were
not treatment related. In the PS, 219 AEs (94
ocular, 125 non-ocular) were reported by 84
patients (44.7%) in the FC treatment arm and
136 AEs (70 ocular, 66 non-ocular) were
reported by 71 patients (38.0%) in the TAF
treatment arm. In total, 8 patients (6 in the FC
and 2 in the TAF treatment arm) discontinued
the study due to AEs in the PS. Treatment-
related AEs leading to study termination in the
PS were ocular in most cases in the FC treatment
arm and included: erythema, eye irritation,
blurred vision, conjunctival/ocular hyperemia,
eye pain, eye pruritus and increased
lacrimation. All terminations in the TAF
treatment arm were related to ocular AEs:
conjunctival hyperemia, conjunctival edema,
erythema of the eyelid, eyelid edema, IOP
increase and blurred vision.
The most frequent ocular AEs (reported for
more than 2 patients) are summarized in
Table 3 for both strata. Most of the ocular
AEs were graded as mild. Conjunctival/ocular
hyperemia was the most frequent treatment-
related AE in both strata. In the TS, treatment-
related hyperemia was reported in 9 patients
(9.5%) in the FC arm and for none in the TIM
treatment arm. The evaluation of conjunctival
redness in patients in the TIM arm also showed
lower levels of redness, and a lower proportion
of patients with low or no redness grading
(Fig. 8a). In the PS, treatment-related
hyperemia was reported in 9 patients (4.8%)
in the FC arm and 6 patients (3.2%) in the TAF
arm. In general, the severity of hyperemia was
mild to moderate. In both strata, the mean
severity of conjunctival hyperemia, evaluated
by reference photographs, was highest at week
2 and showed a decreasing tendency during
the course of the study (Fig. 8a and b). There
were no signs of treatment-related adverse
events of the inner eye optical media and
fundus or visual fields. No significant changes
Fig. 6 Changes of mean (SD) intraocular pressure from
baseline at weeks 2 and 6 and months 3 and 6 at 8 a.m., 10
a.m., 4 p.m. and 8 p.m. in the prostaglandin stratum (PS).
Worse eye analysis in the ITT dataset. FC preservative-free
ﬁxed combination taﬂuprost 0.0015%/timolol 0.5%,
IOP intraocular pressure, ITT Intention to treat, TAF
monotherapy preservative-free taﬂuprost 0.0015%, SD
standard deviation
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of visual fields were revealed post-study in
comparison to the screening visit. All
treatment regimens were generally well
tolerated with approximately 70–80% of
patients experiencing no drop discomfort
upon instillation during the study. Most
discomfort cases were experienced at week 2
in both strata and treatment arms: In the TS,
27 patients (30.0%) reported discomfort (23
mild, 3 moderate and 1 severe) in the FC arm
and 28 patients (30.4%) in the TIM arm (22
mild, 6 moderate). In the PS at week 2, 49
patients (26.2%) reported discomfort (42 mild,
7 moderate) in the FC arm and 41 patients
(22.4%) in the TAF arm (34 mild, 7 moderate).
No statistically significant differences in the
drop discomfort were seen in any of the time
points in either stratum.
DISCUSSION
Fixed combinations of PGAs and timolol are
widely used in glaucoma management because
they offer several advantages; most of all, the
use of one bottle compared to the concomitant
use of the individual components increases
patient convenience. Frequent dosing is
related to poor adherence, thus a simplified
dosing regimen of fixed combinations is likely
to lead to an improvement in patients’
adherence [27]. Furthermore, fixed
combinations eliminate the risk of a wash-out
effect caused by the instillation of a second eye
drop after a too-short interval within a
concomitant treatment regimen. Finally, the
use of fixed combinations decreases, but does
not eliminate the exposure of the eye to
preservatives. There is strong evidence from
both clinical and animal studies that chronic
exposure to preservatives, particularly BAK,
induces ocular surface changes, conjunctival
inflammation, subconjunctival fibrosis,
apoptosis of conjunctival epithelial cells and
corneal surface changes [6, 9, 11, 13]. Moreover,
OSD and dry eye syndrome are very common in
glaucoma patients: several studies report
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Fig. 7 a Scatterplot of mean change in diurnal IOPs
(mmHg) from baseline to month 3 in the PS and
b corresponding box-whisker plot of mean diurnal IOPs
(mmHg) at month 3 versus baseline for FC and TAF. FC
preservative-free ﬁxed combination taﬂuprost 0.0015%/
timolol 0.5%, IOP intraocular pressure, TAF monotherapy
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prevalence rates between 45 and 60% [14, 15,
28]. Preservative-free glaucoma medications are
generally better tolerated than preserved eye
drops [18, 19].
In the present study, we evaluated and
compared the IOP-lowering efficacy, safety and
tolerability of the PF FC of tafluprost 0.0015%
and timolol 0.5% (administered once daily in
the morning) to the individual PF components
tafluprost 0.0015% (administered once daily in
the morning) and timolol 0.5% (administered
twice daily). It is well established that both PF
tafluprost and timolol effectively reduce IOP as
monotherapy [20, 21, 29, 30], are additive in
IOP reduction in concomitant use [25] and
neither of these two substances requires BAK to
enhance its IOP-lowering activity [20–22,
30–32].
The results of this stratified, double-masked,
randomized, multinational, multicenter phase
III study demonstrate that PF FC tafluprost
0.0015%/timolol 0.5% administered once daily
significantly lowered IOP in each stratum, at
each visit and time point during the 6-month
study period. The IOP reduction in the FC
treatment arms of both strata (PS and TS) was
comparable. Mean time-wise IOP reductions
from the corresponding diurnal baseline IOP
levels in the TS ranged between 7.1 and
9.0 mmHg (26.7–34.1%) and 8.2 and
9.0 mmHg (31.2–33.5%) in the PS. These
changes are clinically significant and in a
Table 3 Most frequent treatment-related ocular adverse events (number of patients)
Ocular adverse events TIM stratum (TS) PGA stratum (PS)
FC (n5 95) TIM (n5 94) FC (n5 188) TAF (n5 187)
Conjunctival hyperemiaa 4 0 5 3
Dry eye 2 1 0 3
Eye irritation 2 3 5 0
Eye pain 2 2 7 6
Eye pruritus 4 0 6 3
Eyelid edema 0 0 0 4
Foreign body sensation 3 0 3 2
Ocular discomfort 2 0 0 0
Ocular hyperemiaa 5 0 4 3
Vision blurred 2 1 3 4
Eyelid erythema 0 0 1 2
Eyelash growth 0 0 2 2
Eyelash discolouration 0 0 1 1
Eyelash thickening 0 0 1 1
Photophobia 0 0 1 1
FC preservative-free ﬁxed combination taﬂuprost 0.0015%/timolol 0.5%, PGA prostaglandin analog, TAF monotherapy
preservative-free taﬂuprost 0.0015%, TIM monotherapy preservative-free timolol 0.5%
a The terms ‘‘conjunctival hyperemia’’ and ‘‘ocular hyperemia’’ were used in parallel. Adverse events for this category were
counted only once for each patient
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comparable range to those found for other
preserved prostaglandin/timolol fixed
combinations: Mean diurnal IOP decrease
from baseline with a preserved fixed
combination of latanoprost/timolol was
8.0 mmHg after 13 weeks with untreated
baseline IOP levels that were comparable to
the present study [33]. However, in this study
design patients were treated with timolol 0.5%
twice daily during a 2-week run-in period. In a
study comparing a preserved fixed combination
of bimatoprost/timolol with the individual
components, mean diurnal IOP was decreased
by 8.1 mmHg in the fixed combination
treatment arm [34]. The proportion of patients
achieving a reduction of mean diurnal IOP
of C20% from baseline was 81.8%, which
compares to 85.9% and 89.2% in this study for
the TS and PS, respectively. Finally, a preserved
fixed combination of travoprost/timolol
reduced mean diurnal IOP from untreated
diurnal baseline IOP levels between 27.2 and
30.2 mmHg to IOP levels between 18.7 and
18.2 mmHg at month 3 [35].
The reduction of IOP in the FC treatment arms
was superior to both individual components
administered as monotherapy (PF TIM and PF
TAF). In the TS of the present study, the model-
based difference in IOP at month 3 (ITT LOCF
dataset) between treatment arms (FC–TIM) was
-0.885 mmHg (95% CI from -1.745 to
-0.024 mmHg; p = 0.044); thus the superiority
of FC versus TIM was achieved. The analysis of
sensitivity without the baseline values as
covariate (RM ANOVA) confirmed this finding.
It should also be noted that one outlier in
the FC treatment arm had a substantial effect on
the result. This patient was discontinued after
14 days and the IOP of the unscheduled
withdrawal visit was carried forward in the ITT
dataset until month 3 according to the LOCF
method. After discarding this patient (with data
only from discontinuation visit after 14 days)
from the ITT LOCF dataset, the difference
was -1.138 mmHg (95% CI from -1.897 to
-0.379 mmHg; p = 0.004) in the primary RM
ANCOVA model (Fig. 5; Table 2). Although this
outlier was not removed from the overall
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analysis, it should be noted that it clearly
influences the overall result (Table 2) and
brings forth the conservative nature of the
LOCF analyses. It might further be considered
that timolol has less efficacy than FC over a
complete period of 24 h including night time
IOP measurements due to reduced efficacy of
timolol during the night [36]. On the other
hand, tafluprost monotherapy and the FC may
appear better when a complete 24-h period is
considered.
In the PS, the difference in IOP at month 3
(ITT LOCF) between treatment arms (FC–TAF)
was -1.516 mmHg (95% CI -2.044 to -0.988;
p\0.001); thus superiority of FC versus TAF was
achieved. The sensitivity analysis without the
baseline values as covariate (RM ANOVA)
confirmed these results. In the present study,
the tafluprost/timolol FC was administered at
8:00 a.m. in the morning. In the PS, TAF was
also instilled at 8:00 a.m., which allowed a fair
comparison of the IOP-lowering effect of both
treatment arms. Furthermore, timolol 0.5% was
dosed twice daily in the TS. In general the
evening administration had been slightly
favoring the efficacy of prostaglandin analogs
[23]. In a study conducted by Konstas [37],
morning versus evening dosing of a
concomitant treatment of latanoprost 0.005%/
timolol 0.5% instilled once daily was compared.
Overall, a trend for greater daytime IOP
reduction with evening dosing was found,
whereas morning dosing tended to provide
lower night time pressures [37]. Furthermore,
it could be shown for fixed combinations of
travoprost and timolol, and bimatoprost and
timolol, that evening dosing provided a better
24-h IOP control when compared to morning
dosing [38, 39].
The safety profile of the PF FC of tafluprost
0.0015% and timolol 0.5% was well in line with
the known side effects of timolol and tafluprost.
Specifically, the hyperemia rates of the FC were
very low in both strata: 4.8% and 9.5% for the
PS and TS, respectively, and 6.4% over the two
strata. The reason for the lower hyperemia rate
in the PS compared to the TS may most likely be
explained by the previous exposure of these
patients to prostaglandin therapies. In turn,
conjunctival hyperemia was reported for 22.7%
of the patients at month 3 in the bimatoprost/
timolol fixed combination study [34].
Accordingly, hyperemia was reported for
14.1% of the patients treated with travoprost/
timolol preserved fixed combination [35]. These
rates are considerably higher than those seen in
the present study and suggest that the PF
tafluprost/timolol FC may be better tolerated
and an important treatment option for all
patients who require an effective and safe
combination therapy in clinical practice.
Despite the prospective, multicenter,
randomized, double-masked design and the
large number of patients in each stratum, our
study has limitations. The tafluprost/timolol FC
was administered in the morning. Therefore, we
could not evaluate the potential efficacy
differences between this regimen and the
evening administration of the FC. A direct
comparison of the morning versus evening
dosing of the PF FC of tafluprost 0.0015%/
timolol 0.5% may be needed to reveal possible
efficacy differences of the 2 different dosing
regimens after instillation of the new PF FC.
CONCLUSION
In conclusion, our multicenter, randomized,
double-masked parallel-group study shows that
once daily morning instillation of PF tafluprost
0.0015%/timolol 0.5% FC provides clinically
and statistically significant IOP reductions in
patients with open-angle glaucoma and ocular
hypertension. The IOP reductions are superior
1242 Adv Ther (2014) 31:1228–1246
to those achieved after administering the
individual components, PF tafluprost 0.0015%
and PF timolol 0.5%. The PF FC tafluprost/
timolol was well tolerated and safe, and
associated with a low prevalence of
conjunctival hyperemia.
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